IRA regulations have changed how pharma is approaching innovation in cancer drug...
As post-approval boundaries disproportionately affect rare disease patients, com...
The Phase III VELA programme will compare the IL-17 inhibitor sonelokimab to a p...
AbbVie will pay $48m in upfront costs and up to $665m in milestone payments to l...
The goal had been for 10,000 patients to be on Leqembi by the end of March 2024,...
AGTC-501 is in Phase II development for retinitis in the SKYLINE trial (NCT03316...
Regulatory standards concerning raw material selection are particularly stringen...
Whilst Minerva deals with clinical deficiencies, eyes turn to Karuna’s PDUFA dat...
An unprecedented shortage of cholera vaccine has public health experts fearing t...
A much-anticipated FTC inquiry into pharmaceutical industry middlemen has been s...
BioMarin Pharmaceutical received a subpoena from the U.S. Department of Justice ...
Gonorrhea is on the rise, and growing increasingly resistant to antibiotics. Gep...
An obesity drug from Viking Therapeutics succeeded in a Phase 2 study, helping p...
The scale of the Change Healthcare cyberattack shows the risk of centralized cla...
Decisions made by the FDA more than 20 years ago have come under heightened scru...
In the wake of the Alabama court ruling, debates about “personhood” must remembe...
